Caryn Lerman: An in-depth analysis of tumor DNA for uterine leiomyosarcoma
Caryn Lerman, Director of Norris Comprehensive Cancer Center at Keck Medicine of USC, shared a post on LinkedIn about a paper by Raul Maia Falcao et al. published in Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease:
“Uterine leiomyosarcoma is a rare and aggressive gynecological cancer with survival rates as low as 15%, with only 1,000 cases diagnosed annually in the U.S. Published in Science Direct, Dr. Tirzah Petta, member of the USC Norris Epigenetic Regulation in Cancer Program, and her team conducted an in-depth analysis of tumor DNA and uncovered key genetic mutations (IDH1, KRAS) and a major weakness – homologous recombination deficiency – that could be targeted for treatment. We also identified two distinct tumor types, paving the way for precision medicine.”
Proceed to the video attached to the post.
“Deep multi-omics integration approach reveals new molecular features of uterine leiomyosarcoma”
Authors: Raul Maia Falcao, Jorge Estefano Santana de Souza, Jordi Gonzalez-Molina, William Mathieson, Joseph Carlson, Tirzah Braz Petta.
More posts featuring Caryn Lerman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023